Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 3/20 | 0.62 |
| ▸ | EGFR | P00533 | 6/20 | 0.60 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.58 |
| ▸ | ULK1 | O75385 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 1/20 | 0.54 |
| ▸ | ROS1 | P08922 | 1/20 | 0.54 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771264 | 0.89 | PLK1 (0.63) | PLK1EGFRALKPDGFRBPDGFRA | |
| SCHEMBL3760015 | 0.89 | PLK1 (0.65) | PLK1EGFRALKPDGFRBPDGFRA | |
| SCHEMBL3764374 | 0.87 | PDGFRB (0.75) | PLK1EGFRALKPDGFRBPDGFRA | |
| SCHEMBL3761696 | 0.85 | PLK1 (0.59) | PLK1EGFRALKPDGFRBPDGFRA | |
| SCHEMBL3766732 | 0.85 | PLK1 (0.62) | PLK1EGFRALKULK1AURKA | |
| SCHEMBL3766664 | 0.84 | PLK1 (0.60) | PLK1EGFRALKPDGFRBPDGFRA | |
| SCHEMBL3761718 | 0.84 | PLK1 (0.60) | PLK1EGFRALKULK1AURKA | |
| SCHEMBL3716380 | 0.82 | PLK1 (0.63) | PLK1EGFRALKULK1AURKA | |
| SCHEMBL3760012 | 0.79 | PLK1 (0.64) | PLK1EGFRALKULK1AURKA | |
| SCHEMBL3767425 | 0.76 | ALK (0.68) | EGFRALKAURKAINSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435422-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-12-17 | — | — | EP | claimed |
| US-8486933-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-07-16 | — | — | US | claimed |
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| EP-2435422-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8486933-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2010138578-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | IGF1R, TK1, CDK2 | PLK1 60/4885EGFR 120/4885ALK 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.